Posts by Sandra Ansanay-Alex
$11 million for EPFL spin-off Leman Biotech
A protein that boosts the immune system can cure 90% of cancer in mice Immunotherapy, which aims to boost the patient’s immune system to fight cancer, has no effect in two out of three cases. After a while, T lymphocytes, the main players against cancer cells, become exhausted. To give them a new lease…
Read MoreGSK’s new company Haleon will have a site in Nyon
The pharmaceutical group GlaxoSmithKline creates Haleon, a new company from the separation of its consumer healthcare business. This entity will have a site in the commune of Prangins, part of the district of Nyon. The site currently employs 1,000 people in Prangins and produces 252 million units per year, including the medicines Voltaren and Otrivin.…
Read MoreNeo Medical raises $20 million for its AR technology for spine surgery
Swisscom Ventures is the lead investor in this round. The Vaud-based company will use the new funds to accelerate the commercial deployment of its artificial intelligence-supported augmented reality platform for spinal surgery. With a focus on the US market. Called Advise, the technology “provides surgeons with real-time intraoperative augmented reality (AR) visibility for the first…
Read MoreINTERVIEW : Massimo Nobile
🔺 Massimo Nobile, SwissBiotech Center CEO, explains how digital and life sciences are converging to create new medicines and treatments.
Read MoreMindMaze secures a $105 million financing round
After a banner-year, the Lausanne-based company MindMaze secures $105 Million Financing, led by Concord Health Partners, and initiates American Hospital Association Partnership MindMaze is a pioneer in the multibillion-dollar digital neurotherapeutics market and develops therapeutic solutions for a wide spectrum of neurological diseases. The financing was led by Concord Health Partners (“Concord”), a US-based…
Read MoreLeucine project: a new hub for life sciences in Lausanne
New working spaces at Biopôle Campus Lausanne Biopôle SA, in collaboration with CPEV, is developing the Leucine Building, a new multi-tenant space for companies active in life sciences. It will be operational early 2023. It consists of laboratory and office space that can be customised to its tenants’ needs. Three full floors of up to…
Read MorePhytlSigns raises CHF 500 000 for a plant monitoring system
The ‘Fitbit of Plants’ uses AI sensors to monitor crops The startup Vivent provides growers with a technology to monitor plants’ health and thereby improve both yield and sustainability. The CHF 500 000 Tech Growth loan from the Foundation for Technological Innovation (FIT) will fund the development and launch of a new plant monitoring…
Read MoreINTERVIEW : Raphaël Conz, BioAlps vice-president
🔺 Raphaël Conz, Head of the Business Unit at the Department for the Promotion of the Economy and Innovation of the Canton of Vaud (SPE). The talent of Switzerland, in the field of life sciences, is to bring together academic research and big companies’ interests.
Read MoreSwiss voters reject ban on animal testing
Voters have rejected a complete ban on experiments on living creatures in Switzerland. The idea of putting an end to all experiments on animals in the context of research or scientific studies did not convince the Swiss citizens who voted on 13 February. 79.1% of voters rejected the popular initiative. In Western Switzerland, Geneva…
Read MoreAdaptyv Biosystems raised CHF 2.5 million in a pre-seed funding
Adaptyv Biosystems is to create the world’s largest protein design database The company, based in Biopôle in Epalinges, is active in the field of high-throughput protein synthesis and screening. Using synthetic biology and machine learning, Adaptyv Biosystems massively scales up the number of protein designs that can be explored. In two years’ time, Adaptyv…
Read More